VivoSim Labs, Inc.
NASDAQCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Keith Murphy
- Full Time Employees
- 14
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 11555 Sorrento Valley Road San Diego CA United States of America 92121
- IPO Date
- Feb 14, 2012
- CIK
- 0001497253
- Website
- vivosim.ai
- Similar Companies
- Business
- I did not find relevant results on recent major changes specifically for VivoSim Labs, Inc. (Ticker: VIVS) in the initial search. I will conduct a more targeted search using the company name and ticker specifically with focus on products, latest offerings, partnerships, and corporate news.
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting
VivoSim Platform Predicts Gastrointestinal Toxicity (Diarrhea) in an AI Model Trained on Human Intestinal Model Results – Without Animal Testing
Short Interest in VivoSim Labs, Inc. (NASDAQ:VIVS) Decreases By 69.3%
VivoSim Announces Pricing of up to a $4 Million Public Offering
Head-To-Head Analysis: Agenus (NASDAQ:AGEN) and VivoSim Labs (NASDAQ:VIVS)
VivoSim Releases Antibody Drug Conjugate (ADC) Data Showing Power to Detect ADC Toxicity and Guide Design of Safer ADCs
VivoSim Labs, Inc. (NASDAQ:VIVS) Short Interest Update
VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales
VivoSim Labs, Inc. (NASDAQ:VIVS) Sees Significant Decline in Short Interest
VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
Analyzing Bristol Myers Squibb (NYSE:BMY) & VivoSim Labs (NASDAQ:VIVS)
VivoSim Labs (NASDAQ:VIVS) and MediciNova (NASDAQ:MNOV) Head-To-Head Analysis
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
I Missed The Quantum Rally - I Won't Miss The Next One